Co-PSMA data presented at EAU Annual Congress 2026 with manuscript accepted for publication in the European Urology journal
**media[976998]** HIGHLIGHTSOral presentation on key results from the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT) was delivered by Prof Louise Emmett (St Vincent's Hospital Sydney) at the European Association of Urology (EAU) Congress 2026 on the 16th of March 2026 in London, UK[2].Co-PSMA trial data has also been accepted for publication in the prestigious European Urology, the official journal of EAU with an impressive impact factor of 25.2.Clarity's 64Cu-SAR-bisPSMA (24-hour imaging) demonstrated considerable improvement in diagnostic performance in a head-to-head comparison with standard-of-care (SOC) 68Ga-PSMA-11 positron emission tomography (PET)/computed tomography (CT) in 50 patients with biochemical recurrence (BCR) of prostate cancer with low prostate-specific antigen (PSA; 0.2 - 0.75 ng/mL) who were candidates for curative salvage therapy following radical prostatectomy.The study's primary endpoint was to assess the difference in mean per-patient lesion between 64Cu-SAR-bisPSMA and 68Ga-PSMA-11. Key secondary endpoints included evaluation of diagnostic accuracy against composite reference standard and patient management impact.Mean per-patient lesion was higher for 64Cu-SAR-bisPSMA (24-hour imaging) vs. 68Ga-PSMA-11 (1.26 vs. 0.48, respectively), difference: 0.78 (95% confidence interval [CI]: 0.52 - 1.04) ratio 2.63 (95% CI: 1.64 - 4.20) (p Next-day imaging with 64Cu-SAR-bisPSMA, compared with 68Ga-PSMA-11, identified a greater number of total lesions (63 vs. 24, respectively). The biggest difference in lesion detection between the tracers was in the prostate fossa and in lymph nodes. 64Cu-SAR-bisPSMA also resulted in a higher number of trial participants with a positive scan compared to 68Ga-PSMA-11 (78% vs. 36%, respectively).64Cu-SAR-bisPSMA (24-hour imaging) demonstrated a higher true positive rate (71% vs. 29%) and lower false negative rate (21% vs. 65%) than 68Ga-PSMA-11.64Cu-SAR-bisPSMA next-day imaging resulted in management change in 44% (22/50) of trial participants, with the majority changing from surveillance to targeted radiotherapy.Co-PSMA trial data, combined with Phase II COBRA and anticipated results from a pivotal Phase III AMPLIFY study, are intended to be submitted to the United States (US) Food and Drug Administration (FDA) for a market authorisation of 64Cu-SAR-bisPSMA in patients with BCR of prostate cancer.SYDNEY, March 17, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the results from the Co-PSMA (NCT06907641)[1] IIT were presented by Prof Louise Emmett (St Vincent's Hospital Sydney) in an oral session at EAU Congress 2026, Europe's largest urological conference, on the 16th March in London, UK[2]. The study data has also been accepted for publication in European Urology, the official journal of EAU with an impressive impact factor of 25.2.**media[976999]**
